has strong franchises in ophthalmology, dermatology, and cardiology, plus branded generics in emerging markets. The company focuses on specialty, high‑margin segments and a branded model rather than pure US generics. Healthy balance sheet, R&D capability, and niche product positioning support profitability. Risks are regulatory scrutiny, forex swings from EM exposure, and slower US pipeline scale‑up.

#WatchOutFor#FundamentalViews#TechnicalViews#Miscellaneous#EquityResearch

416 likes·77 comments